BPH is one of those conditions that affects a large population and has physical symptomology that makes sufferers very uncomfortable. These facts make it a great condition for DTC. Unfortunately, ...

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson Watson has launched Rapaflo (silodosin capsules), a selective alpha-1 adrenergic receptor antagonist, for the treatment of the signs and symptoms of ...

A website indicating that Actavis’s alpha-blocker Rapaflo capsules can improve sleep and daytime productivity prompted an untitled letter from the FDA’s Office of Prescription Drug Promotion. The drug ...

April 30, 2009 (Chicago, Illinois) — Results of 2 phase 3 studies reported here yesterday during the American Urological Association (AUA) 104th Annual Scientific Meeting show that silodosin (Rapaflo, ...

CORONA, Calif., Oct. 9 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat the U.S. Food and Drug Administration (FDA) has approved ...

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson The FDA has approved Rapaflo (silodosin, from Watson) for the treatment of benign prostatic hyperplasia (BPH). The FDA has approved Rapaflo (silodosin, ...

Watson Pharmaceuticals scored a victory in its effort to branch out of its generic drug business and launch new branded therapies with today's announcement that it has won regulatory approval to ...

WASHINGTON, Oct. 13 (UPI) -- The U.S. Food and Drug Administration has approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia. "Benign prostatic ...

- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS - WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly ...

CORONA, Calif., Sept. 29 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat investigators presented efficacy and safety data on silodosin, ...

WASHINGTON — A branded drug made by Watson Pharmaceuticals reduced symptoms in men with prostate disease, according to results of a mid-stage clinical trial. Data from the phase-2 study of the drug ...